Status:
UNKNOWN
A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
Lead Sponsor:
Fudan University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
70+ years
Phase:
NA
Brief Summary
PFS
Eligibility Criteria
Inclusion
- .≥65 years or PS 2
- Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small cell lung cancer
- Patients received no chemical therapy or only received targeted therapy,and there is evidence show the patent is PD
- Presence of at least one index lesion measurable by CT scan or MRI
- leucocyte ≥ 3.5×109/L
- neutrophil ≥ 1.5×109/L
- platelet ≥ 80×109/L
- Hemoglobin ≥ 9g/L
- ALT and AST ≤ 2.5×ULN ,Tbil≤ 1.5×ULN
- BUN≤ 1.5×ULN
- Signed written informed consent
Exclusion
- squamous carcinoma or small cell lung cancer
- Patients were allergic to pemetrexed
- Patients received chemotherapy before
- Uncontrolled acute infection
- .Uncontrolled pleural effusion
- Severe symptomatic heart disease
- Severe infection or metabolic disfunction
- Patients with other malignant tumor
- Uncontrolled brain metastases
- Patients have accepted other clinical trials
- Female patients during their pregnant and lactation period, or patients without contraception
- Mental disorientation of disorder
- Glucocorticoids taboo
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT01860508
Start Date
February 1 2013
Last Update
July 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer hospital Fudan University
Shanghai, Shanghai Municipality, China, 200032